Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>Phased industrial deployment roadmap underway. </li><li>The collaboration between Ainos and ASE Technology, the world’s leading semiconductor packaging and testing company, which was established last year, is now activated.</li><li>Under the roadmap, Ainos has initiated Phase 1 of a three-phase deployment of up to 20,000 AI Nose units across ASE' sites. </li></ul>

Phased industrial deployment roadmap underway. The collaboration between Ainos and ASE Technology, the world’s leading semiconductor packaging and testing company, which was established last year, is now activated.Under the roadmap, Ainos has initiated Phase 1 of a three-phase deployment of up to 20,000 AI Nose units across ASE' sites. 

AIMD: Revenue-Generating Commercial Deployment of ASE Agreement Begins

<ul><li>Partnership with Mirle Automation. The partnership with Mirle Automation that was announced on February 2 comes days after Ainos’ Director of Corporate Development indicated that one of the strategic goals of the company is the expansion of its robotics business beyond Japan, which was established in 2025 predominantly through its partnership with ugo.</li><li>In this respect, Taiwan-headquartered Mirle Automation is an expert in intelligent factory automation and robotics with more than 36 years of experience.</li><li>The company is a primary provider of material handling and logistics systems for the semiconductor industry, specifically focusing on advanced packaging and wafer fab automation. </li></ul>

Partnership with Mirle Automation. The partnership with Mirle Automation that was announced on February 2 comes days after Ainos’ Director of Corporate Development indicated that one of the strategic goals of the company is the expansion of its robotics business beyond Japan, which was established in 2025 predominantly through its partnership with ugo.In this respect, Taiwan-headquartered Mirle Automation is an expert in intelligent factory automation and robotics with more than 36 years of experience.The company is a primary provider of material handling and logistics systems for the semiconductor industry, specifically focusing on advanced packaging and wafer fab automation. 

AIMD: New Mirle Partnership Expands AI Nose Robotic Opportunity

<ul><li>AI Nose positions Ainos as an AI perception platform, not a point solution. </li><li>Ainos is enabling AI with the sense of smell by converting scent into standardized “Smell IDs” and training a proprietary Smell Language Model (SLM), effectively adding a new, structured input layer for AI to interpret the physical world. </li><li>Around 13 years of development in high-precision healthcare use cases have demonstrated that smell can be learned over time, providing the technical foundation for expansion into continuous, high-throughput industrial environments.</li></ul>

AI Nose positions Ainos as an AI perception platform, not a point solution. Ainos is enabling AI with the sense of smell by converting scent into standardized “Smell IDs” and training a proprietary Smell Language Model (SLM), effectively adding a new, structured input layer for AI to interpret the physical world. Around 13 years of development in high-precision healthcare use cases have demonstrated that smell can be learned over time, providing the technical foundation for expansion into continuous, high-throughput industrial environments.

AIMD: SmellTech Expansion and Value-Creation Strategy - 2 February 2026

<ul><li>Momentum to scale AI Nose gathers pace in 2026. Ainos has entered the new year by signaling its shift from R&amp;D-focused SmellTech development to commercial deployment built on scalable AI infrastructure. </li><li>At the core of the company’s strategy is a shift beyond hardware sensors to become a core AI infrastructure provider, transforming scent into a scalable platform, serving global industrial markets. </li><li>At the same time, Ainos continues to expand its AI Nose partnership ecosystem through a three-year distribution and deployment agreement with Trusval Technology, a Taiwan-based industrial engineering firm serving semiconductor wafer fabrication facilities, with an initial minimum commitment of 600 AI Nose units.</li></ul>

Momentum to scale AI Nose gathers pace in 2026. Ainos has entered the new year by signaling its shift from R&amp;D-focused SmellTech development to commercial deployment built on scalable AI infrastructure. At the core of the company’s strategy is a shift beyond hardware sensors to become a core AI infrastructure provider, transforming scent into a scalable platform, serving global industrial markets. At the same time, Ainos continues to expand its AI Nose partnership ecosystem through a three-year distribution and deployment agreement with Trusval Technology, a Taiwan-based industrial engineering firm serving semiconductor wafer fabrication facilities, with an initial minimum commitment of 600 AI Nose units.

AIMD: Taking Its SmellTech Leadership to the Next Level Download as PDF | LinkedInTwitter

<ul><li>Key takeaways from 3Q25 earnings release. Lu highlighted Ainos’ strong revenue momentum, up more than 4x Y/Y, driven almost entirely by the deployment of AI Nose in senior care programs.</li><li>Lu noted that the reported revenue has yet to include any of the $2.1-million, three-year AI Nose subscription order from a semiconductor customer, signaling additional upside in the SmellTech platform’s revenue, the turnaround in gross margin to 82% YTD from negative last year, and Ainos’ cost management with cash operating expenses reduced by 15% YTD versus the previous year.</li><li>Lu also highlighted the company’s enhanced visibility through major tech exhibitions resulting in multiple leads, inclusion in a leading tech consultant’s annual tech report, and a GICS code change for the company to technology.</li></ul>

Key takeaways from 3Q25 earnings release. Lu highlighted Ainos’ strong revenue momentum, up more than 4x Y/Y, driven almost entirely by the deployment of AI Nose in senior care programs.Lu noted that the reported revenue has yet to include any of the $2.1-million, three-year AI Nose subscription order from a semiconductor customer, signaling additional upside in the SmellTech platform’s revenue, the turnaround in gross margin to 82% YTD from negative last year, and Ainos’ cost management with cash operating expenses reduced by 15% YTD versus the previous year.Lu also highlighted the company’s enhanced visibility through major tech exhibitions resulting in multiple leads, inclusion in a leading tech consultant’s annual tech report, and a GICS code change for the company to technology.

WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026

United States

Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its smelltech platform, powered by AI Nose and smell language model (SLM), digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Active clinical programs include HIV-related oral warts, primary Sjögren’s syndrome, and feline chronic gingivostomatitis (FCGS). Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ainos (AIMD US)

AIMD: Revenue-Generating Commercial Deployment of ASE Agreement Begins

The collaboration between Ainos and ASE Technology, the world’s leading semiconductor packaging and testing company, which was established last...

Water Tower Research

AIMD: New Mirle Partnership Expands AI Nose Robotic Opportunity

In this respect, Taiwan-headquartered Mirle Automation is an expert in intelligent factory automation and robotics with more than 36 years of...

Water Tower Research

AIMD: SmellTech Expansion and Value-Creation Strategy - 2 February 2026

AI Nose positions Ainos as an AI perception platform, not a point solution. Ainos is enabling AI with the sense of smell by converting scent into...

Water Tower Research

AIMD: Taking Its SmellTech Leadership to the Next Level Download as PDF | LinkedInTwitter

Ainos has entered the new year by signaling its shift from R&D-focused SmellTech development to commercial deployment built on scalable AI...

Water Tower Research

WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026

Lu highlighted Ainos’ strong revenue momentum, up more than 4x Y/Y, driven almost entirely by the deployment of AI Nose in senior care programs.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)